General Comments / Chat, page-75

I am impressed with how this lady can roll off~ Enasidenib , and the (low efficacy - Azacitadine ) standard of care drug name ,,, and say all this at a million miles per hour !

The standard of care drug for R/R AML in older patients - has only 20% complete remission rates generally and less than 12 mths survival overall .
Enasidenib is now approved . It also does not have a great efficacy rate .
The trial she , the oncologist researcher at MD Anderson University of Texas hospital is talking about - is to combine the two .

I would prefer Bisantrene or nothing I think .
When Bisantrene is finally in trials - could Bisantrene be requested, on compassionate grounds ? And provided by Race ? for acute refractory / relapsed myeloid leukaemia or other leukaemias ? If people were to do their own research and it maybe be in trials already for MRD with AML - and in the past over 40 clinical trials , safety and dose known and even children and people who survivors back then - surely individual patients with no hope really under current treatments the that are approved or in trial as combination -
**through their doctors could they ask for and be given , please , Bisantrene ? ( through Race Oncology compassionate use arrangement- Bisantrene is manufactured over there and quantity available - and Borj Andersson associated at MD Anderson )